On January 2, 2026, Sonoma Pharmaceuticals, Inc. announced an annual equity grant to employees, including 10,000 options for non-employee directors and 10,000 RSUs to the CEO at an exercise price of $3.68 per share, vesting over three years. This is a significant event for the company.